2025年10月30日, 生物医药 行业迎来特殊的“管线调整日”。 百时美施贵宝 (BMS)、 礼来 (Eli Lilly)、武田(Takeda)三大跨国药企同步宣布终止6项临床阶段项目,覆盖肿瘤、慢性疼痛、神经疾病等热门治疗领域。这场集中“砍线”不仅是企业对研发管线的动态优化,更折射出当前医药行业在靶点攻坚、成本控制与资产整合中的深层挑战。BMS此次调整涉及两项关键战略资产,均与此前大额投资布局...
Source Link2025年10月30日, 生物医药 行业迎来特殊的“管线调整日”。 百时美施贵宝 (BMS)、 礼来 (Eli Lilly)、武田(Takeda)三大跨国药企同步宣布终止6项临床阶段项目,覆盖肿瘤、慢性疼痛、神经疾病等热门治疗领域。这场集中“砍线”不仅是企业对研发管线的动态优化,更折射出当前医药行业在靶点攻坚、成本控制与资产整合中的深层挑战。BMS此次调整涉及两项关键战略资产,均与此前大额投资布局...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.